Article
Sanofi to cut US price of its most-prescribed insulin by 78%
Rating:
0.0
Views:
58
Likes:
1
Library:
1
Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value